Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
基本信息
- 批准号:10636865
- 负责人:
- 金额:$ 62.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAcuteAdvanced DevelopmentAdverse effectsAffectAnimalsAreaBasal GangliaBehavioralBiological MarkersBrainClinicalClinical ResearchConsumptionDataDeep Brain StimulationDevelopmentDorsalEffectivenessEnergy consumptionEvaluationExperimental DesignsFrequenciesFutureGlobus PallidusGoalsHealthcare SystemsHourImplantIncidenceLeadMeasuresModelingMotorMovementNeurodegenerative DisordersNeuronsNodalOperative Surgical ProceduresOutcomeParkinson DiseaseParkinsonian DisordersPatient CarePatientsPatternPersonsPrefrontal CortexProbabilityQuality of lifeResearchRestSiteStructureStructure of subthalamic nucleusTestingTherapeuticTherapeutic EffectTimeTranslationsUtahWorkbattery lifebattery rechargingdeep brain stimulation arraydensityeffective therapyhuman subjectimprovedmotor disordermotor function improvementmotor symptomneuralneurotransmissionnonhuman primatenovelnovel strategiespreclinical studyside effectspecific biomarkerstherapeutically effectivetranslational therapeutics
项目摘要
PROJECT SUMMARY/ABSTRACT
Parkinson’s disease (PD) is a neurodegenerative disorder affecting 6-7 million people worldwide. Traditional
high frequency, isochronal deep brain stimulation (DBS) is an effective treatment for the motor signs associated
with PD. Clinical outcomes, however, vary across centers and within centers across patients. Adverse effects
can be induced by “current-spread” to unintended brain areas when the DBS lead is sub-optimally placed which
limits clinical benefits. Coordinated reset (CR) DBS is a promising novel DBS approach that has the potential to
overcome the limitations of traditional DBS. By alternating lower intensity stimulation delivered in a burst pattern
across different contacts of the DBS lead, CR DBS is associated with less current spread, thus reducing the
incidence of adverse effects, and improvement in motor signs that persist for days to weeks after cessation of
stimulation, i.e. carryover effect. Although the effectiveness of CR DBS has been demonstrated in both preclinical
and clinical studies, the selection of CR parameters that provide the greatest carryover effect has been
challenging. The optimal target for CR DBS must also be identified. The proposed study using a within-subject
experimental design will 1) optimize the critical parameter (cycle rate) of CR DBS, (2) compare the effect of CR
DBS in the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi), and (3) characterize
the changes in cortical and subcortical neuronal activities associated with its therapeutic effect. The nonhuman
primate model of PD will be used with each animal implanted with DBS leads in the STN and GPi and high-
density Utah arrays placed over the primary motor, dorsal premotor and dorsolateral prefrontal cortices.
Objective and quantitative motor assessments will be performed to measure the acute and carryover effect of
CR DBS with different cycle rates and in different targets (STN and GPi). The central hypothesis is that the
therapeutic effect of CR DBS is greatest when the cycle rate is based on subject-specific pathophysiological
biomarkers associated with the PD state. We further hypothesize that CR DBS in GPi will provide greater acute
benefits in motor signs and induce significantly longer carryover effects. We predict that motor improvements
induced by CR DBS will correlate with a reduction in synchronized neuronal activity within and across cortical
and subcortical nodal points in the basal-ganglia-thalamocortical (BGTC) circuit. The results of this study will
provide a time efficient approach for the selection of CR DBS cycle rate based on subject-specific biomarker
activity in the BGTC circuit, identify the optimal target for CR DBS and enhance our understanding of the
mechanism(s) underlying the therapeutic effect of CR DBS. Results of the study will significantly advance the
development of CR DBS for the treatment of PD that will enhance clinical outcomes, prolong battery life and
induce fewer side effects leading to higher quality of life for PD patients undergoing DBS.
项目总结/摘要
帕金森病(PD)是一种神经退行性疾病,影响全球600 - 700万人。传统
高频等时脑深部电刺激(DBS)是治疗相关运动体征的有效方法
PD的。然而,临床结果在不同中心和不同患者的中心内各不相同。不利影响
当DBS电极导线放置在次优位置时,
限制了临床获益。协调复位(CR)DBS是一种有前途的新型DBS方法,
克服了传统DBS的局限性。通过交替以突发模式递送的较低强度刺激
在DBS电极导线的不同触点上,CR DBS与较小的电流扩散相关,从而降低了
不良反应的发生率,以及停止后持续数天至数周的运动体征改善
刺激,即携带效应。尽管CR DBS的有效性已在临床前和临床试验中得到证实,
和临床研究,选择CR参数,提供最大的遗留效应,
挑战性还必须确定CR DBS的最佳靶点。使用受试者内
实验设计将1)优化CR DBS的关键参数(循环率),(2)比较CR DBS的效果,
丘脑底核(subthalamic nucleus,DBS)和苍白球内段(internal segment of the globus pallidus,GPi)的DBS,以及(3)表征
皮层和皮层下神经元活动的变化与其治疗效果有关。非人
PD的灵长类动物模型将用于在MRI和GPi中植入DBS电极导线的每只动物,
密度犹他州阵列放置在初级运动,背侧前运动和背外侧前额叶皮质。
将进行客观和定量运动评估,以测量
具有不同周期率和不同靶点的CR DBS(SPECT和GPi)。核心假设是,
当周期率基于受试者特定的病理生理学时,CR DBS的治疗效果最大
与PD状态相关的生物标志物。我们进一步假设,GPi中的CR DBS将提供更大的急性
运动体征的益处,并诱导显著更长的残留效应。我们预测,
由CR DBS诱导的脑缺血将与皮质内和皮质间同步神经元活动的减少相关
以及基底神经节-丘脑皮质(BGTC)回路中的皮质下节点。这项研究的结果将
根据受试者特异性生物标志物,为选择CR DBS周期率提供了一种时间效率高的方法
BGTC回路中的活动,确定CR DBS的最佳目标,并增强我们对
CR DBS治疗效果的潜在机制。研究结果将大大促进
开发用于治疗PD的CR DBS,这将改善临床结局,延长电池寿命,
导致更少的副作用,从而提高接受DBS的PD患者的生活质量。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of subthalamic coordinated reset deep brain stimulation on Parkinsonian gait.
- DOI:10.3389/fninf.2023.1185723
- 发表时间:2023
- 期刊:
- 影响因子:3.5
- 作者:Bosley, Kai M.;Luo, Ziling;Amoozegar, Sana;Acedillo, Kit;Nakajima, Kanon;Johnson, Luke A.;Vitek, Jerrold L.;Wang, Jing
- 通讯作者:Wang, Jing
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jing Wang其他文献
Electrochemical performance of high-capacity nanostructured Li[Li0.2Mn0.54Ni0.13Co0.13]O2 cathode material for lithium ion battery by hydrothermal method
水热法制备锂离子电池高容量纳米结构Li[Li0.2Mn0.54Ni0.13Co0.13]O2正极材料的电化学性能
- DOI:
10.1016/j.electacta.2013.05.118 - 发表时间:
2013-09 - 期刊:
- 影响因子:6.6
- 作者:
Xin Wei;Shichao Zhang;Zhijia Du;Puheng Yang;Jing Wang;Yanbiao Ren - 通讯作者:
Yanbiao Ren
Jing Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jing Wang', 18)}}的其他基金
Targeting Sigma 1 receptor as a novel therapy for limiting neurovascular injury in ROP
靶向 Sigma 1 受体作为限制 ROP 神经血管损伤的新疗法
- 批准号:
10718424 - 财政年份:2023
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10267675 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10413216 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10030344 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer
靶向 TGFbeta/PDK4 克服结直肠癌耐药性
- 批准号:
10000912 - 财政年份:2018
- 资助金额:
$ 62.56万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 62.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 62.56万 - 项目类别:
Operating Grants